SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-3.6%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$614M
AUM Growth
+$614M
(-0.65%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-10.49%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
127
New
28
Increased
29
Reduced
33
Closed
11
Top Buys
| 1 |
Skye Bioscience
SKYE
|
$10.4M |
| 2 |
ASML
ASML
|
$10.1M |
| 3 |
Apple
AAPL
|
$9.27M |
| 4 |
Amazon
AMZN
|
$9.08M |
| 5 |
Salesforce
CRM
|
$8.64M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$116M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$17.9M |
| 3 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$9.57M |
| 4 |
Camtek
CAMT
|
$9.14M |
| 5 |
Nova
NVMI
|
$6.23M |
Sector Composition
| 1 | Healthcare | 71.02% |
| 2 | Technology | 20.47% |
| 3 | Communication Services | 3.65% |
| 4 | Consumer Discretionary | 3.59% |
| 5 | Utilities | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $23.1M | 3.14% | 910,070 +324,114 | +55% | +$8.21M |
|
2
Sanofi
SNY
$121B
| $21.8M | 2.97% | 449,515 -50,000 | -10% | -$2.43M |
|
3
Cytokinetics
CYTK
$4.23B
| $20.9M | 2.84% | 384,924 +103,253 | +37% | +$5.59M |
|
|
4
Amazon
AMZN
$2.44T
| $19.6M | 2.67% | 101,432 +47,000 | +86% | +$9.08M |
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.9M | 2.3% | 822,047 +9,083 | +1% | +$186K |
|
6
Meta Platforms (Facebook)
META
$1.86T
| $16.9M | 2.3% | 33,439 +8,000 | +31% | +$4.03M |
|
7
AstraZeneca
AZN
$248B
| $14.8M | 2.02% | 190,060 | – | – |
|
8
Microsoft
MSFT
$3.77T
| $14.7M | 2.01% | 32,927 +5,379 | +20% | +$2.4M |
|
9
Nice
NICE
$8.73B
| $14M | 1.91% | 81,461 -4,420 | -5% | -$760K |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $13.2M | 1.8% | 83,659 +28,045 | +50% | +$4.43M |
|
|
11
Apple
AAPL
$3.45T
| $13M | 1.77% | 61,500 +44,000 | +251% | +$9.27M |
|
|
12
Teva Pharmaceuticals
TEVA
$21.1B
| $12.8M | 1.75% | 789,416 -1,100,284 | -58% | -$17.9M |
|
13
Kura Oncology
KURA
$686M
| $12.6M | 1.72% | 610,826 | – | – |
|
14
Ultragenyx Pharmaceutical
RARE
$2.89B
| $12.1M | 1.65% | 293,832 +55,288 | +23% | +$2.27M |
|
15
Eli Lilly
LLY
$657B
| $11.9M | 1.63% | 13,190 -1,000 | -7% | -$905K |
|
16
Praxis Precision Medicines
PRAX
$958M
| $11.7M | 1.6% | 283,424 +106,285 | +60% | +$4.4M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $11.4M | 1.56% | 309,265 +32,269 | +12% | +$1.19M |
|
18
Novo Nordisk
NVO
$251B
| $11.1M | 1.52% | 78,080 -5,000 | -6% | -$714K |
|
19
Biogen
BIIB
$19.4B
| $11M | 1.5% | 47,412 -23,234 | -33% | -$5.39M |
|
|
20
Skye Bioscience
SKYE
$108M
| $10.4M | 1.42% | +1,298,312 | New | +$10.4M |
|
21
Jasper Therapeutics
JSPR
$45.5M
| $10.3M | 1.41% | 454,227 -51,015 | -10% | -$1.16M |
|
22
Johnson & Johnson
JNJ
$427B
| $10.2M | 1.39% | 69,831 -10,000 | -13% | -$1.46M |
|
|
23
ASML
ASML
$292B
| $10.1M | 1.38% | +9,901 | New | +$10.1M |
|
24
Merus
MRUS
$4.98B
| $8.74M | 1.19% | 147,633 -1,700 | -1% | -$101K |
|
|
25
Salesforce
CRM
$245B
| $8.64M | 1.18% | +33,600 | New | +$8.64M |
|